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CASE REPORT
Abstract: Phantom bite syndrome is characterized by an uncomfortable sensation mainly
affecting corrected dentition in which no abnormality is clinically detectable. Despite repeated
failures of dental surgery, sufferers persist in seeking bite correction from a succession of
dentists. The etiology–pathogenesis of phantom bite is unknown but some consider the
syndrome to be a psychosomatic disorder. Seven patients with this syndrome were treated
with the serotonin and norepinephrine reuptake inhibitor milnacipran for 4 weeks. One patient
withdrew after 2 weeks because he was feeling “well”. At the end of the study, 5 of the 6
patients completing the study reported significant improvements, with a mean decrease in
occlusal discomfort of 55.3%, as indicated by a visual analogue scale. This result appeared to
be independent of any antidepressant effect. Only minor and transient side-effects were
observed. It is suggested that milnacipran may be a helpful treatment for phantom bite but
this needs to be confirmed by further and longer term studies.
Keywords: phantom bite syndrome, occlusal discomfort milnacipran oral psychosomatic
disorders
Introduction
There is a subgroup of patients with temporomandibular disorder who nomadically
pass from one dentist to another seeking “bite correction”. Their occlusal discomfort
is characterized by an uncomfortable sensation mainly affecting corrected dentition,
crowns, or dentures in which no abnormality is clinically detectable. This phenomenon
is known as the phantom bite syndrome (Marbach 1976, 1978; Marbach et al 1983;
Jagger and Korszun 2004). Despite repeated failures of dental surgery, these
individuals persist in seeking bite correction from a succession of dentists. The
condition is refractory to most treatments including psychotherapy (Marbach 1976, 1996).
We have reported previously that tricyclic antidepressants can be effective in
treating phantom bite syndrome (Toyofuku 2000). However, the patients’ non-
acceptance of the anticholinergic side-effects of these drugs usually prevents high
enough doses being achieved. Milnacipran is an antidepressant which, similarly to
the tricyclics, inhibits the reuptake of serotonin and norepinephrine but without the
side-effects of the older antidepressants. Recently it has been reported that milnacipran
has been used to treat various oral psychosomatic disorders such as glossodynia and
temporo-mandibular disorder (Toyofuku 2003; Toyofuku et al 2003; Toyofuku and
Miyako 2004).
We present here a preliminary study of the efficacy and safety of milnacipran in
a series of patients complaining of occlusal discomfort and diagnosed as suffering
from phantom bite syndrome.
Subjects
We report here the results with 7 patients who came to the Department of Dentistry
and Oral Surgery at the Fukuoka University Hospital in Japan in 2003–2004
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complaining of occlusal discomfort and diagnosed as
suffering from phantom bite syndrome. Six patients were
outpatients and one was hospitalized for severe fatigue and
because of difficulty of attending the hospital since she lives
on a remote island.
All patients met the following criteria;
1) preoccupation with their dental occlusion and a false
belief that their dental occlusion was abnormal,
2) a long history of repeated dental surgery treatment failures
with persistent requests for the occlusal treatment that they
are convinced they need,
3) no history of significant psychiatric illness,
4) absence of obvious psychosocial problems. They all had
a relatively high intelligence and socioeconomic status
which enabled then to undergo endless costly and time-
consuming dental treatments.
Methods
The patients were treated for 4 weeks in an open study.
No dental or psychotherapeutic interventions were
allowed during the study. Milnacipran was initially
administered at 30 mg/day on a twice daily schedule and
adjusted weekly according to clinical symptoms and
tolerance.
The effect on occlusal discomfort was measured using a
100 mm visual analogue scale (VAS) where baseline severity
was arbitrarily set to 100. Severity of depression was
assessed using the Zung Self-Rating Scale for Depression
(SDS). The clinical global improvements were graded by
the treating clinician as “marked” (marked improvement
with only occasional mild symptoms), “mild” (some
improvement but with considerable residual symptoms), or
“poor” (little or no improvement).
Results
Baseline and demographic data of the 7 patients are given
in Table 1. One patient was lost to follow-up after 2 weeks
because he refused to continue, stating that he was “feeling
well”. Five of the remaining 6 patients were improved at
the end of the 4-week treatment period, 3 markedly, and 2
mildly improved.
Patient 6 was unco-operative and refused to complete
the VAS and SDS self-rating evaluations at the end of the
study. She insisted, however, that she had had no
improvement at all over the 4 weeks of the study. During
the study she refused any increase of the dose of milnacipran,
insisting on dental surgery bite correction instead of
medication. Scores of 0 improvement were therefore used
for this patient for the SDS and VAS analyses (Table 2).
Overall, the occlusal discomfort felt by the patients was
considerably decreased between baseline and week 4 (Table
2). The mean decrease, as indicated by the VAS, was 55.3%.
Table 1 Demographic and baseline data
Case nr Age Sex Duration of SDS Type of
complaint (baseline) dental
(months) treatment
1 51 F 24 60 implants
2 29 F 42 53 orthodontic
3 55 F 6 55 crowns
4 54 F 15 57 crowns
5 63 M 24 61 full-denture
6 66 F 36 52 bridges
7 58 F 132 73 crowns
Mean 53.7 39.9+42.4 58.7+7.1
(+SD) +12.1
Abbreviations: SDS, Zung Self-Rating Scale for Depression.
Table 2 Results after 4 weeks of treatment with milnacipran
Case nr Maximum Symptom Clinical Depressive Side-effects
milnacipran severity global symptoms
dose VAS improvement SDS
(mg/day) (% decrease)
1 120 46 Mild 32 -
2 45 34 Mild 20 Headache
3 50 73 Marked 23 -
4 50 87 Marked 28 -
5
a 60 Lost to follow-up after 2 weeks
6b 30 0 Poor 52 Dizziness
7 100 92 Marked 23 Nausea
Mean(+SD) 65.0+32.5 55.3+35.4 29.7+11.7
aPatient 5 was lost to follow-up after 2 weeks. The patient discontinued because he was “feeling well”.
bPatient 6 was unco-operative and refused to complete the VAS and SDS self-rating evaluations at the end of the study. She insisted, however, that she had had no
improvement at all over the 4 weeks of the study. Score of 0 improvement were therefore attributed for this patient and the SDS was considered to be unchanged.
Abbreviations: SDS, Zung Self-Rating Scale for Depression; VAS, visual analogue scale.Neuropsychiatric Disease and Treatment 2006:2(3) 389
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The level of depressive symptoms was also decreased as
indicated by a 47.8% decrease in SDS. There was, however,
no correlation between individual reductions in SDS and
VAS values.
The mean final dose of milnacipran was 65.0 mg/day.
Three patients reported adverse effects (headache, dizziness,
and nausea, Table 2). All effects, however, were slight and
transient, disappearing within a few days. No serious side-
effects were observed.
Discussion
Patients exhibiting the phantom bite syndrome are
considered to be refractory to most dental treatment. They
become increasingly difficult to manage after repeated
failures of dental surgery resulting in frustration for both
the dentist and the patient who is usually convinced of the
incompetence of their dentist and moves on to another
dentist.
The present study suggests that milnacipran may be a
beneficial treatment for such oral psychosomatic disorder
patients with occlusal discomfort known as phantom bite
syndrome.
The present study included 7 patients. While in absolute
terms this is a small number, it is the largest study on
phantom bite to have been reported to date. The Department
of Dentistry and Oral Surgery at Fukuoka University has
an excellent reputation in the treatment of dental
psychosomatic disorders and for this reason patients are
referred to this department by psychosomatic doctors from
all over southern Japan. In addition 40% of patients in the
present study came spontaneously to the department because
of its reputation among patients.
In addition to the small number of patients, the obvious
weakness of the study resides in its open-label design. The
possibility of a placebo effect cannot be ruled out. However,
the refractory nature of the disorder (the average duration
at the beginning of the study was over 3 years) gives some
credence to the observed results.
The quantification of subjective sensations is always
difficult. In the present study a visual analogue scale was
used to assess the degree of occlusal discomfort. This
technique probably lacked precision, however, since some
of the patients said they had difficulty in expressing
quantitatively their symptom on a visual analogue scale.
The development of other patient-rated measures such as a
modified “faces scale” as used to quantify pain in children
(Bieri et al 1990) would clearly be helpful for studying this
and similar oral psychosomatic conditions.
None of the patients had any history of significant
psychiatric illness, indeed they were all strongly resistant
to the idea of psychiatric referral or treatment. Six of the 7
patients were, however, mildly depressed as rated by the
Zung SDS scale and one more moderately depressed. In 5
out of 6 patients completing the study, the depression scores
improved considerably to a level considered to be
asymptomatic. In general, however, there was no
correlation in this study between the decrease in SDS
score and decrease in occlusal discomfort as indicated
by the VAS. This result and clinical observations suggests
that the efficacy of milnacipran in reducing occlusal
discomfort is more likely to be a direct effect on the
somatosensory system rather than on any associated
depression.
Milnacipran and other serotonin-norepinephrine
reuptake inhibitors have been shown to be effective on a
variety of pain disorders both associated with, and
independent of, depression (Briley 2003, 2004). Milnacipran
is not, however, an analgesic as such and these effects have
been suggested to involve an action on serotonin and
norepinephrine neurotransmission (Stahl and Briley 2004).
The action of milnacipran appears to be to correct the
erroneous integration of peripheral signals by the central
nervous system. A further example of milnacipran correcting
erroneous integration of peripheral signals is in
fibromyalgia where normally non-painful stimuli are
perceived as pain signals (allodynia) (Vitton et al 2004).
It would seem likely that the effect of milnacipran on
phantom bite seen in the present study is another
manifestation of this activity on the two monoamines
systems where the occlusal discomfort experienced by
the patient is the result of an erroneous integration of
peripheral signals.
In conclusion, after 4 weeks treatment, 5 of the 6 patients
completing the study responded to milnacipran with
clinically significant improvements in their occlusal
discomfort. This suggests that milnacipran may be an
effective and well tolerated treatment for phantom bite in
oral psychosomatic disorder patients. Phantom bite is,
however, a chronic syndrome and the promising effects seen
here after 4 weeks need to be followed up over a much longer
time period.
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